Key Slides on Emerging Insights on Adverse Events During ART and Implications for Treatment

Gain expert insight on the impact of emerging ART safety and tolerability data on ART initiation and switch strategies.
Joseph J. Eron, Jr., MD
Darcy Wooten, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 571 KB
Released: May 11, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Educational grant provided by
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

CCO commentary by Dr. Gregory Huhn on ART and weight gain including perspectives and new data on potential pathophysiology and implications

Gregory Huhn, MD, MPHTM Released: June 17, 2021

Clinical Care Options’ (CCO) commentary from a person with HIV on what it was like living through the COVID-19 pandemic as a long-term HIV survivor

person default Frank Primavera Released: June 9, 2021

Latesha Elopre and CCO: starting HIV pre-exposure prophylaxis (PrEP). DISCOVER study, CDC guidance, racial/ethnic disparities, overcoming barriers

Latesha Elopre, MD, MSPH Released: June 7, 2021

Slides from CCO: Switching ART in HIV: 3-drug therapy, oral 2-drug options, long-acting injectable 2-drug regimens, single tablet regimens (STRs)

Daniel R. Kuritzkes, MD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Released: June 7, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue